Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · FibroBiologics, Inc. (FBLG)

FibroBiologics stockholders approve warrant shares; CSO buys $0.5 million in stock

Neutral Impact 3 of 5 shareholder Written later

At a September 17, 2026 special meeting, FibroBiologics stockholders approved the issuance of up to 8,163,266 shares under warrants tied to a June 25, 2026 Securities Purchase Agreement and up to 285,714 shares under warrants tied to an H.C. Wainwright engagement letter, for purposes of Nasdaq Listing Rule 5635(d). Separately, Chief Scientific Officer Hamid Khoja closed a private placement on September 15, 2026 for 298,508 shares and accompanying warrants, with gross proceeds of about $0.5 million.

Key points

  • Special meeting held September 17, 2026; 3,431,761 of 8,283,193 votes entitled to be cast (record date July 20, 2026) were represented.
  • Warrant share issuance proposal approved: 3,153,098 for, 258,217 against, 20,446 abstain.
  • Approval covers up to 8,163,266 shares under the June 25, 2026 SPA warrants and up to 285,714 shares under H.C. Wainwright warrants.
  • Khoja private placement closed September 15, 2026 at $1.675 per share-and-warrant unit, priced at-the-market; warrants exercisable at $1.55 for five years.

The filing

CompanyFibroBiologics, Inc. (FBLG)
Form8-K, current report
Filed with the SECSep 18, 2026, 4:05 PM ET
Accession number0001193125-26-395511

Items reported: 5.07 Shareholder Vote Results7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.